Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Acadia Pharmaceuticals |
3.68 Bn |
2.83 Bn |
243.27 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
-98.67% |
| Dec 31, 2025 |
281.13% |
| Sep 30, 2025 |
169.18% |
| Jun 30, 2025 |
40.44% |
| Mar 31, 2025 |
-86.79% |
| Dec 31, 2024 |
338.71% |
| Sep 30, 2024 |
-1.87% |
| Jun 30, 2024 |
101.69% |
| Mar 31, 2024 |
-63.85% |
| Dec 31, 2023 |
170.27% |
| Sep 30, 2023 |
-5,950.63% |
| Jun 30, 2023 |
102.59% |
| Mar 31, 2023 |
-3.23% |
| Dec 31, 2022 |
-53.40% |
| Sep 30, 2022 |
20.02% |
| Jun 30, 2022 |
69.95% |
| Mar 31, 2022 |
-162.35% |
| Dec 31, 2021 |
-198.08% |
| Sep 30, 2021 |
67.05% |
| Jun 30, 2021 |
33.98% |
